John Maraganore was the founding CEO and a director of Alnylam Pharmaceuticals - the leading RNAi therapeutics company - which he led for nearly 20 years from 2002-2021. John built and led the company from early platform research on RNAi through global approval and commercialization of the first five RNAi medicines including ONPATTRO®, GIVLAARI®, OXLUMO®, LEQVIO® and AMVUTTRA®. At Alnylam, he led the company’s value creation strategy, raising over $7.5B in capital, forming over 20 major pharmaceutical alliances and creating over $25B in market capitalization.

Prior to Alnylam, John held senior leadership roles at Millennium Pharmaceuticals, Inc., and at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, marketed by The Medicines Company. Prior to Biogen, John was a scientist at ZymoGenetics, Inc., and the Upjohn Company.

John is currently the CEO and principal of JMM Innovations, LLC, committed to the advancement of biomedical innovation to patients. He serves on the boards of Beam Therapeutics, Kymera Therapeutics, Rapport Therapeutics and Takeda Pharmaceuticals, in addition to a number of private company and non-profit boards. He is a member of the Biotechnology Innovation Organization board, where he was Chair from 2017-2019.

John received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago.